MTIP AG: MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
(Basel, Switzerland): MTIP FUND II, SCSp is MTIP’s second healthtech fund, designed to provide growth capital and build on the healthtech investment thesis of its successful predecessor. With a target size of EUR 200m the fund invests in digital health and connected medical device companies, based primarily in Europe, that offer differentiated solutions for a rapidly evolving healthcare environment.
MTIP’s second fund executed a strong first closing securing EUR 130m. The capital was raised by different investors comprising mainly institutional investors, pension funds, family offices, hospitals, and foundations. The company is proud to work together with the European Investment Fund (EIF) as an anchor investor. EIF’s Chief Executive Alain Godard said: “MTIP’s fund strategy fits with EIF's ambition of financing the vital growth segment of the European Venture Capital ecosystem, which is largely underfunded and overly dependent on non-European investors for larger investments. The EIF is pleased to support MTIP and tackle two major gaps in the European market - digital health and growth capital.”
"This closing is an enormously important milestone in our company history, and we are pleased to have overachieved our expectations. Our Fund II has already added three stellar investments in Oviva, Trialbee and Koa Health to its portfolio with more to come soon. This creates a strong momentum towards the final close", emphasizes Dr. Christoph Kausch, Managing Partner of MTIP. The Fund continues to see a unique flow of investment opportunities, enhanced by the firm’s network, its leading role in Europe, and the strength of its strategy.
About MTIP
MTIP is a fast-growing pan-European healthtech growth capital investor, based in Basel Switzerland. We invest in digital health and digitally connected medical device companies, with offerings that provide clear health-related economic benefits. Our entrepreneurial investment team, which has complementary private equity skills and exceptional deal-making capabilities, actively works with our portfolio companies to boost growth. MTIP efficiently deploys capital to unlock value and generate attractive returns for our investors. Visit www.mtip.ch for more information
Contacts
Dr. Christoph KauschManaging Partner
communications@mtip.chLinks
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
New management for the EUTOP Group22.4.2024 10:51:42 CEST | Press release
Stefan Mappus is the new Managing Director of the EUTOP Group. Together with long-standing Managing Director Christian Schaufler, he will manage the fortunes of the Group from now on. Stefan Mappus is responsible for EUTOP's client business as a member of the management board and thus brings his wealth of experience in politics, administration and business directly to the benefit of EUTOP's clients.
Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria18.4.2024 10:15:00 CEST | Press release
Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology. BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes. Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend t
Elatec Brings Employee Badge for Apple Wallet to Users17.4.2024 08:45:03 CEST | Press release
Munich, April 17, 2024 – Elatec today announced it is bringing employee badge in Apple Wallet to its customers, enabling an organization’s employees or tenants to unlock access to locations and devices with a simple tap of their iPhone or Apple Watch. Powered by Elatec’s Mobile Credential Manager software, which works hand-in-hand with Elatec’s universal RFID readers, this brings together the world’s most powerful and versatile readers with the best mobile access system available. Employee badge in Apple Wallet helps deliver a convenient and contactless experience for users. Once enabled, employee badge in Apple Wallet allows users to seamlessly and securely add their employee badge to Apple Wallet, and hold their iPhone or Apple Watch near an NFC reader to unlock office doors, turnstiles, elevators and key card-protected amenity spaces — eliminating the need to open an app or present a traditional, plastic access key. With Express Mode, employees do not need to unlock their device to
National Research Center for Applied Cybersecurity ATHENE: Severe Vulnerabilities Discovered in Software to Protect Internet Routing12.4.2024 08:49:14 CEST | Press release
A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key Infrastructure (RPKI). RPKI is an Internet standard meant to protect Internet traffic from being hijacked by hackers. By now, all affected vendors provided patches for their products. The vulnerabilities could have had devastating consequences: Internet hijacks have already been exploited, e.g., for phishing passwords and other sensitive information, tricking certificate authorities into issuing fraudulent Web certificates, stealing cryptocurrency, distributing malware, and poisoning caches of DNS servers.
Dr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment10.4.2024 11:00:00 CEST | Press release
The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom